Seeking Alpha

Pharmacyclics close to new highs after Lazard upgrade

  • Shares of Pharmacyclics (PCYC +1.4%) are trading around their 52-week (and all-time) highs.
  • Helping the cause is Lazard, where analysts upgraded the shares to Buy from Neutral earlier today.
  • Recently: FDA accepts ibrutinib NDA for two B-cell malignancy indications.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)